December 26, 2014 3:34 AM ET

Healthcare Providers and Services

Company Overview of National Institutes of Health

Company Overview

National Institutes of Health operates as a medical research agency in the United States. It offers services for conducting and supporting basic, clinical, and translational medical research; and investigates the causes, treatments, and cures for common and rare diseases. The company also provides leadership and direction to programs designed to improve the health by conducting and supporting research in the causes, diagnosis, prevention, and cure of human diseases; in the processes of human growth and development; in the biological effects of environmental contaminants; in the understanding of mental, addictive, and physical disorders; and in directing programs for the collection, dissemina...

9000 Rockville Pike

Bethesda, MD 20892

United States

Founded in 1887

Phone:

301-496-4000

Fax:

301-402-2984

Key Executives for National Institutes of Health

Chief Financial Officer and Deputy Director of Management
Chief Information Officer
Deputy Director of Extramural Research
Deputy Director of Intramural Research
Compensation as of Fiscal Year 2014.

National Institutes of Health Key Developments

National Institutes of Health Presents at BioFlorida Annual Conference, Oct-13-2014 11:30 AM

National Institutes of Health Presents at BioFlorida Annual Conference, Oct-13-2014 11:30 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Sitta Sittapalam, Senior Scientific Officer & Project Manager.

Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens

Spring Bank Pharmaceuticals, Inc. announced a research collaboration with the National Institutes of Health (NIH) for animal testing of the Company's lead compound, SB 9200, against multiple viral pathogens, classified as "Special Pathogens," against which currently there are no effective antiviral therapies. SB 9200, derived from Spring Bank's proprietary Small Molecule Nucleic Acid Hybrid (SMNH) technology platform, is a novel, broad-spectrum anti-viral agent that uniquely acts by selectively modulating the host immune response to viral infections. SB 9200 has recently completed a Phase 1b clinical trial for treatment of Hepatitis C (HCV) and is also being developed for the treatment of Hepatitis B Virus (HBV) and Respiratory Syncytial Virus (RSV).

National Institutes of Health to Launch Human Safety Study of Ebola Vaccine Candidate

National Institutes of Health announced Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will evaluate the experimental vaccines safety and ability to generate an immune system response in healthy adults. Testing will take place at the NIH Clinical Center in Bethesda, Maryland. The study is the first of several Phase 1 clinical trials that will examine the investigational NIAID/GSK Ebola vaccine and an experimental Ebola vaccine developed by the Public Health Agency of Canada and licensed to NewLink Genetics Corp. The others are to launch in the fall. These trials are conducted in healthy adults who are not infected with Ebola virus to determine if the vaccine is safe and induces an adequate immune response. In parallel, NIH has partnered with a British-based international consortium that includes the Wellcome Trust and Britains Medical Research Council and Department for International Development to test the NIAID/GSK vaccine candidate among healthy volunteers in the United Kingdom and in the West African countries of Gambia (after approval from the relevant authorities) and Mali. Additionally, the U.S. Centers for Disease Control and Prevention has initiated discussions with Ministry of Health officials in Nigeria about the prospects for conducting a Phase 1 safety study of the vaccine among healthy adults in that country. The pace of human safety testing for experimental Ebola vaccines has been expedited in response to the ongoing Ebola virus outbreak in West Africa. According to the World Health Organization (WHO), more than 1,400 suspected and confirmed deaths from Ebola infection have been reported in Guinea, Liberia, Nigeria, and Sierra Leone since the outbreak was first reported in March 2014. There is an urgent need for a protective Ebola vaccine, and it is important to establish that a vaccine is safe and spurs the immune system to react in a way necessary to protect against infection.

Similar Private Companies By Industry

Company Name Region
McCulley/Cuppan LLC United States
Wesley Homes Corporation United States
Med Advantage, Inc. United States
Health Care Services Inc. United States
Morristown-Hamblen HomeCare and Hospice, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 9, 2014
Retrotope, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact National Institutes of Health, please visit www.nih.gov. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.